Non-neuronal functions of the M2 muscarinic acetylcholine receptor by Ockenga, Wymke et al.
Genes 2013, 4, 171-197; doi:10.3390/genes4020171 
 
genes
ISSN 2073-4425 
www.mdpi.com/journal/genes 
Review 
Non-Neuronal Functions of the M2 Muscarinic Acetylcholine 
Receptor  
Wymke Ockenga, Sina Kühne, Simone Bocksberger, Antje Banning and Ritva Tikkanen * 
Institute of Biochemistry, Medical Faculty, University of Giessen, Friedrichstrasse 24, 35392 Giessen, 
Germany; E-Mails: Wymke.Ockenga@biochemie.med.uni-giessen.de (W.O.); 
Sina.Kuehne@biochemie.med.uni-giessen.de (S.K.); Simonebocksberger@web.de (S.B.); 
Antje.Banning@biochemie.med.uni-giessen.de (A.B.) 
* Author to whom correspondence should be addressed;  
E-Mail: Ritva.Tikkanen@biochemie.med.uni-giessen.de;  
Tel.: +49-641-9947-420; Fax: +49-641-9947-429. 
Received: 31 January 2013; in revised form: 10 March 2013 / Accepted: 25 March 2013 /  
Published: 2 April 2013 
 
Abstract: Acetylcholine is an important neurotransmitter whose effects are mediated by 
two classes of receptors. The nicotinic acetylcholine receptors are ion channels, whereas 
the muscarinic receptors belong to the large family of G protein coupled seven 
transmembrane helix receptors. Beyond its function in neuronal systems, it has become 
evident that acetylcholine also plays an important role in non-neuronal cells such as 
epithelial and immune cells. Furthermore, many cell types in the periphery are capable of 
synthesizing acetylcholine and express at least some of the receptors. In this review, we 
summarize the non-neuronal functions of the muscarinic acetylcholine receptors, especially 
those of the M2 muscarinic receptor in epithelial cells. We will review the mechanisms of 
signaling by the M2 receptor but also the cellular trafficking and ARF6 mediated 
endocytosis of this receptor, which play an important role in the regulation of signaling 
events. In addition, we provide an overview of the M2 receptor in human pathological 
conditions such as autoimmune diseases and cancer.  
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1. Introduction to Acetylcholine and Its Receptors 
In the early 1920s, Otto Loewi identified the neurotransmitter acetylcholine as a substance that 
displays an inhibitory effect on heart functions. Due to its apparent release by the vagus nerve, 
acetylcholine was nDPHG ³9DJXVVWRII´ ,Q WKH 60s, this discovery led to the detection of the 
respective acetylcholine binding nicotinic and muscarinic receptors [1±3]. Besides their function in the 
central nervous system, acetylcholine receptors have been shown to display important functions in 
non-neuronal cells. In fact, many peripheral cells of our body are capable of synthesizing acetylcholine 
and express at least some of the receptors. The nicotinic acetylcholine receptors are ion channels. 
Represented by five subtypes, namely M1, M2, M3, M4 and M5, the muscarinic acetylcholine receptors 
(mAChRs) belong to the seven transmembrane helix receptor superfamily which activate trimeric 
guanine nucleotide binding proteins (G proteins) [4,5]. The genes encoding the five mAChRs are 
found in different genetic loci in humans: 11q12-13 (CHRM1), 7q35-36 (CHRM2), 1q43-44 
(CHRM3), 11p12-p11.2 (CHRM4) and 15q26 (CHRM5). The mAChR genes are highly compact in 
that they do not contain any introns, and the resulting gene products are highly homologous among 
mammalian species [5,6]. 
In general, mAChR subtypes are differentially expressed in various cell lines and tissues, which all 
seem to express several receptor types. The expression pattern results in functional differences, which 
may sometimes be hard to assign to a specific receptor type. The non-neuronal functions of muscarinic 
receptors are summarized in Section 2. 
On the basis of their signaling mechanism, mAChRs can be divided into two major classes [7]. The 
stimulation of M1, M3 and M5 receptor subtypes increases the intracellular calcium concentration upon 
binding of pertussis toxin insensitive G proteins (Gq/11) and mediates the activation of the membrane 
bound enzyme phospholipase C (PLC) [8,9]. In contrast, M2 and M4 receptors mainly regulate the 
inhibition of adenylyl cyclase and the activation of potassium conductivity via pertussis toxin sensitive G 
proteins of the Gi and Go classes. However, all mAChRs can in principle affect adenylyl cyclase activity 
and thus lead to an increase or decrease of cAMP by means of non-canonical signaling [10,11]. The 
mechanisms of muscarinic receptor signaling are more closely reviewed in Section 3. 
In structural terms, the muscarinic receptors consist of seven relatively well conserved 
transmembrane domains (TM). These domains are connected through three extracellular loops, 
including the extracellular amino terminus, which exhibits a high variability among the five mAChR 
subtypes, and three intracellular loops. In addition to the TMs, it has been reported that the C-terminal 
tail of the M2 receptor is associated with membranes by palmitoylation [12]. The acetylcholine binding 
cavity is formed by the extracellular face of the TMs, with TM3 providing the bottom of the cavity, 
whereas TM2 and TM7 narrow it down. In an activated state, the mAChRs bind G proteins within their 
third intracellular loop and catalyze GDP-GTP exchange, leading to downstream signaling 
events [10,13]. In this review, we have focused on the muscarinic receptor subtype M2 whose 
structure, signaling and cellular trafficking are the subject of Section 4. In this section, we also 
summarize the importance of the small GTPase ARF6 for the endocytosis and trafficking of the M2 
receptor and G protein coupled receptors (GPCRs) in general. 
Muscarinic AChRs frequently are targets of autoantibodies, resulting in autoimmune diseases. Due 
to their function in muscle contraction, they have also been suggested to participate in the pathogenesis 
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of e.g., lung diseases. Importantly, it is known that mAChR subtypes play a key role in various 
cancers. Section 5 provides a short summary of the role of muscarinic receptors, especially that of the 
M2 receptor, in human diseases. Concluding remarks and future directions are addressed in Section 6.  
2. Functions of Muscarinic Acetylcholine Receptors in Non-neuronal Cells 
The functions of the different muscarinic receptor subtypes in the non-neuronal cholinergic system 
are diverse, depending on the distribution of single receptor subtypes in different tissues. Cells 
expressing mAChRs can be found virtually everywhere in the body. They are present e.g., in the 
epithelial layer of the airways, the skin, the immune system, the urinary bladder, reproductive organs, 
vascular endothelial cells, connective tissue, muscles and even tendons. Genetically ablated mice have 
been generated for all five muscarinic receptor subtypes [14±18]. These mice are viable and show no 
major developmental defects. However, some specific functions of receptor subtypes have been 
conclusively demonstrated in these mice (Summarized in [19]). In this paper, we are not aiming at 
providing an exhaustive review of the non-neuronal mAChR functions. For this, the reader should 
refer to recent excellent reviews in this topic [20±22].  
Keratinocytes of the skin display the mRNA for all five muscarinic subtypes, and acetylcholine 
apparently plays a role in migration, differentiation, proliferation and adhesion of the cells [23±25]. In 
keratinocytes, it was shown that, in conjunction with nicotinic AChRs, muscarinic receptors are also 
necessary e.g., for the development of epithelial architecture and thus barrier formation. M1 and M4 
receptors are well expressed in the suprabasal layer of the human skin, whereas M2, M3 and M4 receptors 
are found especially in the basal layer, as shown by in situ hybridization and antibody staining of skin 
sections [3,20]. As keratinocytes synthesize and secrete acetylcholine for autocrine stimulation, it is 
plausible that the secreted acetylcholine also affects melanocytes which express M1 through M5 
receptors, detectable both at mRNA and protein level [26]. The migration of human keratinocytes is 
regulated in a reciprocal manner by two different muscarinic receptors. On the one hand, the M4 receptor 
induces migration and wound re-epithelialization, whereas M3 inhibits these processes. Accordingly, the 
M4 receptor XSUHJXODWHVWKHH[SUHVVLRQRIWKHLQWHJULQVĮȕĮ9ȕDQGĮ9ȕ, which are connected to 
the movement of the cell, and the M3 receptor FDXVHVWKHH[SUHVVLRQRIWKHLQWHJULQVĮȕDQGĮȕthat 
promote a sedentary state of the cell [27]. In fact, an acetylcholine gradient has even been shown to 
induce the migration of skin keratinocytes upwards in the epidermis [28]. 
The urothelium of the urinary bladder also expresses all of the muscarinic receptor subtypes of 
which M2 is the most prominently expressed one. Quantitative PCR and immunohistochemistry 
experiments showed that M1 and M2 are predominantly expressed by specific cell types in the 
urothelium. The M1 receptor is found in basal cells, and the M2 receptor shows a high expression in 
umbrella cells. M3 and M4 receptors are more homogenously distributed, and the M5 receptor content 
decreases from luminal to the basal cells [29]. Furthermore, the M3 receptor seems to be important for 
the contraction of the detrusor muscle [30] and generally appears to be the major regulator of smooth 
muscle contraction, as evidenced by knockout mouse studies [19].  
In the epithelium of the airways, the M1 receptor plays a vital role. Together with nicotinic 
acetylcholine receptors, it stimulates the proliferation of the epithelial cells [31]. Moreover, ciliar 
activity, chloride secretion and thus the mucociliary clearance are mediated by muscarinic receptors [32]. 
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Furthermore, M3 receptors stimulate while M2 receptors inhibit the cilia driven particle transport in the 
airways [33]. In addition to these receptor subtypes, the M4 receptor is highly abundant in peripheral lung 
tissues and has been suggested to play a role in autoinhibition of acetylcholine release in the trachea [34]. 
In regard to mediation of parasympathetic control, the M2 receptor is so far considered as the only 
muscarinic receptor subtype able to influence cardiac functions, e.g., heart rate or contractility. However, 
also M1 and M3 receptor proteins are expressed in the membrane of human cardiac cells [35] and 
participate in the control of the blood circulation system. Some major vasoactive mediators are nitric 
oxide, endothelium derived hyperpolarizing factor and prostanoids. All these substances are supplied by 
endothelial cells upon stimulation of their muscarinic receptors. Acetylcholine release itself might be 
regulated by the blood flow, shearing forces and blood pressure and may therefore modulate the release 
of the vasoactive mediators [22]. In line with this, release of acetylcholine has been shown as a 
consequence of increased blood flow in cultured human umbilical vein endothelial cells [36]. 
The non-neuronal cholinergic system also plays an important role in the immune system. The 
mRNAs for all five muscarinic receptors are present in most human mononuclear leukocytes, human 
leukemic cell lines and also in animal immune cells [20,37,38]. During immunological reactions, the 
autocrine and paracrine stimulation of macrophages, T cells or dendritic cells induces immune 
responses such as the expression of interleukin-2 and its receptor [8,38]. Depending on the immune 
status, the expression of muscarinic receptors varies in T cells. In non activated CD4 and CD8 cells, 
M1, M3, M4 and M5 receptors are present. This pattern changes upon activation of the cells via T cell 
receptor crosslinking, in that M1 and M5 receptors become upregulated in CD4 cells. In contrast, CD8 
cells show an increased expression of M1 and M4 receptors, while the M3 receptor is 
downregulated [39]. Nevertheless, the M5 receptor seems to be the most important muscarinic receptor 
subtype in B and T cells, as the mRNA of this receptor subtype is upregulated upon activation in many 
of these cell types. The immunological activation therefore requires the cholinergic transmission for 
correct cell differentiation [40]. M5, together with M1 receptors, is also involved in modulation of the 
immune system as it is important for the regulation of cytokine production [41]. Another fundamental 
mechanism in the human body that is regulated by the non-neuronal cholinergic system is the release 
RILQVXOLQIURPȕ-pancreatic cells, which serves to maintain glucose homeostasis. It is mainly induced 
by glucose but at the same time, it can also be facilitated by muscarinic receptors. In this context, it is 
the M3 receptor delivering the stimulatory effects on the insulin release and potentiating it [42]. 
3. Signaling by the Muscarinic Acetylcholine Receptors 
The muscarinic acetylcholine receptors belong to the family of GPCRs, comprising seven 
transmembrane domains. They initiate the signal transduction through their coupling with 
heterotrimeric guanine nucleotide binding proteins, the so called trimeric G proteins. These G proteins 
FRQVLVWRIĮ-ȕ- and Ȗ-subunits which couple to the muscarinic receptors mainly DWWKHUHFHSWRU¶VWKLUG
intracellular (i3) loop. However, the second intracellular loop and the C-terminus have also been 
suggested to be involved [43]. Upon binding of a ligand, GPCRs are conformationally rearranged. This 
results in an exchange of bound GDP WR*73LQWKHĮ-subunit, which then leaves the complex, whereas 
WKHȕ- DQGȖ-subunits stay together to facilitate signal transduction. There are several isoforms of the G 
proteins, and due to their preferential coupling to a different subset, muscarinic receptors can be divided 
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into two distinct groups. The M1, M3 and M5 receptor subtypes preferentially couple to Gq/11, whereas 
M2 and M4 receptors couple to Gi/o. Depending on the class of the G protein involved, different 
downstream effectors are activated in a cell upon receptor stimulation. The typical signaling pathways 
of mAChRs are summarized in Figure 1. Through their linkage to Gq/11, M1, M3 and M5 receptors 
predominantly aFWLYDWH 3/& YLD WKH Į-subunit. The activation of PLC results in production of 
diacylglycerol (DAG), which is generated together with inositol trisphosphate (IP3) upon the 
hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) by PLC. This path facilitates the 
mobilization of intracellular Ca2+ and activation of the protein kinase C (PKC). On the other hand, M2 
and M4 receptors mainly inhibit the adenylyl cyclase through their corresponding G proteins, leading 
to a decrease in cAMP levels. However, this provides only a simplified view of the basal signaling 
events, and there are a lot more proteins involved in the fine tuning and regulation. In addition, the ȕȖ-
dimer is also able to participate in the signal transduction.  
,Q DFFRUGDQFHZLWK WKH IDFW WKDW WKHUH DUH Į- ILYH ȕ- DQG Ȗ-subunit isoforms in the human 
genome for the heterotrimeric G proteins [44], several different signaling pathways can be stimulated 
by the muscarinic receptors. For example, phospholipase D (PLD) can be activated via G12 coupled to 
M3 receptors [45], and M2 as well as M3 receptors can activate the sphingosine kinase to mobilize Ca2+ 
via sphingosine-1-phosphate [46]. Furthermore, the signaling can be influenced by the Regulator of G 
protein Signaling (RGS) proteins which can accelerate the inactivation of G proteins and thus reduce 
their signaling [47]. Muscarinic receptors are also able to act on different ion channels in the cell 
membrane. Whereas M2 and M4 receptors can directly activate inward rectifying potassium channels 
YLDWKHLUȕȖ-subunits [48], the M1 receptor can inhibit this conductance [49]. In addition, M1, M3 and 
M5 receptors have the ability to activate calcium channels, which has been shown to be dependent on 
G protein activation [50,51]. 
A large scale approach to identify interaction partners of muscarinic receptors was done by  
Borroto-Escuela et al. by means of a tandem affinity purification method and subsequent mass 
spectrometry [52,53]. A wide number of proteins were selectively recruited upon carbachol stimulation 
of a specific receptor. For the M1 UHFHSWRUWKHVHLQFOXGHG3/&ȕG protein coupled kinases GRK2 
and GRK6, as well as the focal adhesion kinase. Proteins that were detected together with M1 receptors 
even in unstimulated neuroblastoma cells were caveolin-1 and - ȕ-tubulin and ADP ribosylation 
factor 6 (ARF6). The trimeric G proteins thDW ZHUH IRXQG WR EH UHFHSWRU DVVRFLDWHG ZHUH WKH *Į
isoforms q, 11, 12 and 13 for M1, M3 and M5 UHFHSWRUV DQG *Į L L DQG L IRU WKH 02 and  
M4 UHFHSWRUV)XUWKHUPRUHDVVRFLDWLRQRI*ȕLVRIRUPVDQGDVZHOODV*ȖLVRIRUPVDQGZDV
also identified. 
A downstream signaling cascade that is accessed by all subtypes of muscarinic receptors is the 
mitogen activated protein (MAP) kinase pathway. For M1, M3 and M5 receptors, the activation of the 
MAP kinase pathway typically involves the activation of 3.& 7KLV FDVFDGH LQFOXGHV WKH *Įq/11 
mediated activation of PLC and the resulting production of DAG and IP3, as described above. In human 
neuroblastoma SK-N-BE2(C) cells, the MAP kinase pathway proceeds via a sequential activation of Ras, 
Raf and MEK [54], whereas in the case of M1, M3 and M5 receptors, the involvement of Raf but not Ras 
is more typical [55,56]. Beside these, there are pathways leading to the phosphorylation and therefore 
activation of the extracellular signal regulated kinases ERK1/2, which are PKC independent. In some 
cases, the signaling is mediated by the GȕȖ dimer and Src or phosphatidylinositol 3-kinases 
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(PI3K) [57,58]. Other alternative pathways for these receptors to activate MAP kinases, in a PKC 
dependent or independent manner, involve a subset of G proteins different from Gq/11 [59,60]. Even 
though all muscarinic receptor subtypes can accomplish the activation of ERK1/2, not all of them 
significantly contribute to ERK activation in a single cell type. In PC12D cells, M1, M4 and M5 receptor 
mRNAs are present but only the M1 receptor appears to contribute to the phosphorylation of ERK1/2, 
although M1 represents only a small proportion of the population of muscarinic receptors at the protein 
level in these cells [59]. M2 and M4 UHFHSWRUVSUHIHUHQWLDOO\XWLOL]HWKHȕȖVXEXQLWVRI*i for the signaling 
to the MAP kinases. In COS- FHOOV WKLV SDWKZD\ LQYROYHV WKH UHFUXLWPHQW RI 3,.Ȗ WR WKH SODVPD
membrane and the activation of a tyrosine kinase, as well as Shc, Grb2, Sos, Ras and Raf, which at the 
end results in the phosphorylation of ERK1/2 [61].  
Figure 1. Canonical signaling of muscarinic receptors. The muscarinic acetylcholine 
receptors (mAChRs) DUH FRXSOHG WR WULPHULF * SURWHLQV WKDW FRQVLVW RI Į- ȕ- DQG Ȗ-
subunits. M2 and M4 receptors couple preferentially to Gi/0, whereas M1, M3 and M5 
receptors mainly couple to Gq/11. Upon stimulation with acetylcholine or a related agonist, 
M2 and M4 receptors inhibit the activity of the adenylyl cyclase (AC), leading to a decrease 
in intracellular cAMP levels. In addition, both receptor subgroups can activate ion 
channels. M1, M3 and M5 receptors activate PKC by means of upstream PLC activation and 
increase in IP3 and Ca2+ levels. PKC can activate Raf kinase, leading to the activation of 
the MAP kinase cascade and ERK1/2. Pathways that are common for all receptor subtypes 
are the activation of ERK1/2 via a Src/PI3K pathway or transactivation of the EGF 
receptor. Transactivation of EGFR by M2 and M4 receptors occurs in a Fyn dependent 
mechanism, whereas M1, M3 and M5 utilize matrix metalloproteases (MMP) that release 
extracellular, EGF like peptides.  
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Beside ERK1/2, the c-Jun N-terminal kinases (JNKs) are another group of MAP kinases that can be 
targets of muscarinic signaling. In COS-7 cells, they are brought into action via M1 and M2 receptors in 
a Ras and Rac1 GHSHQGHQWPDQQHU LQGXFHGE\WKHȕȖ-subunits of the receptors [62]. However, JNKs 
FDQDOVREHDFWLYDWHGYLDWKHĮ-subunit of a GPCR, aVLVWKHFDVHIRUWKHĮ-subunit of G11 coupled to the 
M1 receptor in human embryonic kidney (HEK)-293 cells [63]. The activation of JNKs can occur 
simultaneously with ERK1/2, as ERK1/2 and JNK are both activated by overexpressed M3 receptors in 
Chinese hamster ovary (CHO) cells. On the contrary, ligand binding to M2 receptors expressed at a 
comparable level only results in the phosphorylation of ERK1/2. Activation of ERK1/2 through these 
pathways has been shown to be independent of changes in the intracellular Ca2+ concentration [64]. 
Further members of the MAP kinase family, the p38 mitogen-activated protein kinases, can also be 
stimulated by the muscarinic receptors. The activation of p38 by M1 receptors involves the Į- and  
ȕȖ-subunits, whereas the M2 receptor only utilizes WKH ȕȖ-subunits in HEK 293 cells [65]. This 
pathway is also dependent on PKC and Src kinase signaling [63].  
After ligand binding and stimulation, muscarinic receptors are desensitized in a process that is 
dependent on receptor phosphorylation at serine and threonine residues by members of the GRK 
family [66]. These GRKs only work on agonist bound receptors, thus leading to a specific 
desensitization after stimulation. PKRVSKRU\ODWLRQ RI WKH UHFHSWRU DOORZV ȕ-arrestins to bind, which 
suppresses the G protein interactions and therefore terminates the signal. In unstimulated cells, GRKs 
are located in the cytoplasm and only translocate to the receptors at the plasma membrane upon 
VWLPXODWLRQ7KH\ELQGWRWKHUHOHDVHGȕȖ-subunits and PIP2 [67]. This desensitization process underlies 
a negative feedback loop, as ERK1/2 can phosphorylate GRK2 and decrease its activity [68,69]. 
Besides its role in desensitization, the phosphorylation of muscarinic receptors is also important for 
thHLULQWHUQDOL]DWLRQ$JDLQȕ-arrestins are involved in most cases, and their binding is necessary for an 
accurate endocytosis of the muscarinic receptors. However, WKH GRPLQDQW QHJDWLYH ȕ-arrestin mutant 
V35D only displayed a significant effect on M1, M3 and M4 receptor sequestration, indicating that the 
UHFHSWRU VXEW\SHV PD\ GLIIHU LQ WKHLU UHTXLUHPHQW IRU ȕ-arrestin [70]. Upon internalization, the 
receptors can either be resensitized or degraded. Resensitization can be blocked by applying protein 
phosphatase inhibitors, likely through inhibition of receptor dephosphorylation in the endosomal 
compartments [71]. 
4. The M2 Muscarinic Acetylcholine Receptor 
4.1. Structural Features of the M2 Receptor  
The M2 receptor subtype is apparently different from all the other muscarinic receptors in several 
respects. Even though the M2 receptor is coupled to Gi/o, similarly to M4 receptor, it exhibits some 
properties that are characteristic only for this receptor subtype. Whereas all other muscarinic receptors 
are resensitized and recycled back to the plasma membrane in different cell types, the M2 receptor is 
usually downregulated by degradation [72]. Furthermore, its internalization appears to differ in the 
UHTXLUHPHQWIRUȕ-arrestin and dynamin [70,73]. 
The most important structural part of the M2 receptor that facilitates the signaling process is, as with 
the other subtypes, the i3 loop of the receptor. The structure of the M2 receptor is depicted in Figure 2. 
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A recent study has described the atomic structure of the M2 receptor, revealing interesting common 
features but also differences to other muscarinic receptors [74]. Unfortunately, this structure does not 
contain the i3 loop which turned out to be too flexible to allow for a structure determination at a 
sufficiently high resolution. The i3 loops of the muscarinic receptors are relatively long and consist of 
160 to 240 amino acid residues. They represent the part of the receptor that is responsible for most of 
the differences between the single subtypes. The first and second intracellular loops show sequence 
similarities of approximately 90% between receptor subtypes, whereas the i3 loops merely feature 40% 
identity in their amino acid sequence, accompanied by a high variability in their length [52]. The i3 
loop of the M2 receptor exhibits a flexible structure without specific secondary structure elements, 
except for the region at the C- and N-WHUPLQDOSDUWWKDWPD\IRUPĮ-helices [75]. A short sequence of 
four amino acids at the C-terminal end of the i3 loop, close to the sixth TM, mediates the coupling of 
the M2 receptor WRWKHĮ-subunit of Gi/0 [76]. The i3 loop is also the most important section where the 
ȕȖ-subunits of the heterotrimeric G proteins bind. Furthermore, it is phosphorylated by GRK2 upon 
stimulation and plays an important role in receptor internalization [77±79].  
Figure 2. Structure of the M2 receptor. The M2 muscarinic acetylcholine receptor belongs 
to the family of G protein coupled receptors. The seven transmembrane domains (TM1-7) 
are connected by intracellular or extracellular loops, and the receptor exhibits four 
glycosylation sites at its extracellular N-terminal domain. The serine residues 96 and 176 in 
the first and second extracellular loop are connected to each other by a disulfide bond. 
Except for the third intracellular (i3) loop, other loops are relatively small. The i3 loop 
consists of 181 amino acids and has no specific secondary structure. The C-terminal 
domain and the i3 loop can be phosphorylated at several residues. 
 
The M2 receptor¶VDIILQLW\ IRU its ligand, the internalization and efficiency of signal transduction can 
be influenced by the cholesterol content of the plasma membrane, and depletion of cholesterol leads to a 
reduced ligand affinity, lower rates of receptor internalization but an increased inhibition of the adenylyl 
cyclase [80]. However, although this would suggest the involvement of the cholesterol rich, lipid raft like 
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microdomains, M2 receptors are not localized in rafts at the plasma membrane of Madin-Darby Canine 
Kidney (MDCK) cells, and rafts are not involved in their apical targeting [81]. In polarized MDCK cells, 
the apical sorting signal for the M2 receptor was found to reside in the i3 loop [81]. However, the apical 
targeting of M2 receptors in polarized MDCK cells is independent of glycosylation, and the expression 
and correct function of the receptor do not require glycosylation [81,82]. 
It has become clear that the M2 receptor is not found as a monomer but that it homo-oligomerizes to 
a certain degree [83]. Using fluorescence resonance energy transfer approaches, the M2 receptor was 
identified to reside in the membrane of CHO cells as a tetramer [84]. Beyond that, the existence of 
hetero-oligomers was discussed, and analysis using bioluminescence resonance energy transfer could 
demonstrate the formation of such oligomers between M1, M2 and M3 receptors [85]. The interaction 
between M2 and M3 receptors is likely to be mediated by electrostatic interactions between the i3 
loops [86]. Heterodimerization between M2 and M3 receptors has also been suggested by the data 
showing that coexpression of both receptors in JEG-3 cells results in increased lysosomal degradation 
of the M3 receptor which normally displays robust recycling rather than degradation [85]. This was 
attributed to a more dominant effect of the M2 receptor, which is predominantly sorted in the 
lysosomal pathway instead of being recycled.  
4.2. Signaling of the M2 Muscarinic Acetylcholine Receptor 
As a Gi/o coupled receptor, the main effect of M2 receptor stimulation could be expected to be the 
inhibition of the adenylyl cyclase and a decrease in cellular cAMP levels. However, this appears not 
always to be the case. In CHO cells expressing M2 receptors, for example, also the net synthesis of 
cAMP can be stimulated upon agonist binding to the M2 receptor. In these cells, the M2 receptor also 
seems to couple to Gs or Gq/11, thus changing the outcome of the receptor signaling [87]. 
Very important downstream targets of the M2 receptor signaling are the MAP kinases ERK1/2, 
which can be activated by different signaling pathways. In M2 receptor expressing COS-7 cells, the G 
SURWHLQȕȖ-subunits coupled to the M2 receptor are able to induce the phosphorylation of ERK1/2 via 
the PI3KȖas a part of a pathway that involves a tyrosine kinase, Shc, Grb2, Sos, Ras and Raf [61], but 
WKHĮ-subunit can also be involved in ERK1/2 activation [88]. An isoform of Rap1 GTPase-activating 
protein, rap1GAPII, FDQELQGVSHFLILFDOO\WRWKHĮ-subunits of the Gi family. Upon stimulation of the 
M2 receptor, rap1GAPII decreases the amount of GTP bound Rap1. As active Rap1 antagonizes Ras 
function, the resulting inactivDWLRQ RI5DS UHSUHVHQWV DZD\RI WKH Į-subunit of the Gi coupled M2 
receptor to facilitate ERK1/2 activation [88]. The transactivation of the epidermal growth factor 
receptor (EGFR) can also contribute to MAP kinase signaling following the stimulation of GPCRs. 
Upon extracellular ligand stimulus, EGFR dimerizes, its tyrosine kinase activity is promoted, and it 
becomes autophosphorylated. Thus, its downstream signaling pathways are activated and contribute to 
ERK1/2 phosphorylation. In fact, our unpublished data show that in HaCaT keratinocytes, most of the 
ERK activation upon carbachol stimulation can be attributed to EGFR transactivation. The 
transactivation has been shown in several cell lines [89], and it may involve the activation of matrix 
metalloproteases (MMP) that lead to the proteolytic release of EGF like peptides from the cell 
surface [90,91], as already demonstrated for M1 and M3 receptors [92,93]. However, for the M2 
receptor an MMP independent mechanism dependent on the protein tyrosine kinase Fyn was 
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established. In COS-7 cells transiently overexpressing M2 receptor, the M2 receptor mediated 
transactivation upon carbachol stimulation leads to an incomplete EGFR downstream signaling 
towards ERK1/2 and Akt, ZKHUHDV3/&ȖLVQRWDFWLYDWHG [94]. The authors postulated that differences 
in the tyrosine phosphorylation profiles of the EGFR might be generated depending on the activation 
mechanism, and the transactivation thus can result in an incomplete signaling.  
The interaction of ȕ-arrestin with ERK1/2 is thought to inhibit its translocation to the nucleus, thus 
restricting the ERK signaling of GPCRs to the cytoplasm and changing the outcome of the ERK 
signaling [95,96]. Importantly, ȕ-arrestins do not only inhibit the nuclear translocation but also 
function as scaffolds that bring together ERK2, MEK1 and Raf-1 [95]. An endosomal localization was 
observed for the overexpressed M2 receptor, ERK1/2 DQG ȕ-arrestins in HeLa cells upon carbachol 
stimulation, whereas a more diffuse cytoplasmic GLVWULEXWLRQ RI ȕ-arrestin was detected after 
stimulation upon overexpression of the other muscarinic receptors [97]. As the DVVRFLDWLRQRIȕ-arrestin 
with the M2 receptor is stable only after stimulation, it is possible that the mechanisms of ERK1/2 
activation differ to a great extent between the M2 receptor and the other muscarinic receptors. It can be 
hypothesized that the prolonged interaction of M2 receptor ZLWKȕ-arrestin might play a role to restrict 
the signal of this receptor subtype to the cytoplasm. Together with the G protein mediated ERK 
DFWLYDWLRQ WDUJHWHG WR WKH QXFOHXV WKH ȕ-arrestin mediated cytoplasmic signaling provides additional 
possibilities for the control of MAP kinase activity and substrates that become phosphorylated, 
applying a high level of complexity to the modulation of signaling.  
Upon agonist stimulation, the M2 receptor is rapidly phosphorylated on serine/threonine residues by 
second messenger kinases such as protein kinase A (PKA) or by specific G protein receptor kinases, 
e.g., GRK2 which appears to be the main kinase for the M2 receptor [98]. The targets of GRK2 are the 
serine and threonine residues in the central part of the i3 loop [99], and overexpression of a dominant 
negative GRK2 mutant together with the M2 receptor in HEK cells leads to a complete loss of M2 
receptor desensitization [100]. Phosphorylation of the serines and threonines within the amino acid 
residues 307 to 311 upon receptor stimulation allows ȕ-arrestin binding [101] which is required for the 
termination of M2 receptor signaling by disrupting the interaction of the receptor and its coupled G 
protein. It has been suggested that the phosphorylation dependent process of M2 receptor 
LQWHUQDOL]DWLRQLV LQGHSHQGHQWRIȕ-arrestins and does not require clathrindependent endocytosis [101]. 
+RZHYHU VWXGLHV LQPRXVH HPEU\RQLF ILEUREODVWGHULYHG IURPȕ-arrestin deficient mice showed that  
ȕ-arrestin is indeed required for M2 receptor endocytosis [97]. The phosphorylation of M2 receptor in 
the i3 loop upon stimulation seems to act as a sigQDOIRUGHVHQVLWL]DWLRQDQGPD\KHOSWKHȕ-arrestins to 
overcome a putative inhibitory signal that precludes inappropriate receptor binding [102]. Some 
aspartic and glutamic acid residues in close proximity to the phosphorylation sites are essential for an 
adequate response to receptor phosphorylation. However, they rather appear to be involved in  
ȕ-arrestin binding than directly in phosphorylation, as mutating them into asparagines and glutamines 
had no effect on UHFHSWRUSKRVSKRU\ODWLRQEXWLPSDLUHGȕ-arrestin binding [103]. 
4.3. Receptor Internalization and Its Connection to Signaling 
Resensitization of GPCRs involves their dephosphorylation after endocytosis [104]. However, 
different from all the other muscarinic receptor subtypes, the M2 receptor is not resensitized in most 
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cases and does not recycle back to the plasma membrane [72]. Figure 3 summarizes the main features 
of the M2 receptor endocytosis. While the internalization of the M2 receptor seems to be important for 
signal termination by means of receptor degradation, it does not seem to play a major role in the 
temporal regulation of the signaling. A comparative study of the extent and kinetics of receptor 
internalization for the different muscarinic receptor subtypes in CHO cells showed that the M2 receptor 
internalizes faster and more extensively than all the other receptors. Its degree of downregulation was 
comparable to those of M3, M4 and M5 receptors, and only the M1 receptor displayed a more intense 
degradation. The M1, M3 and M5 receptor downregulation exhibits a rapid component after a short 
term treatment with carbachol and a slower component for further downregulation upon long term 
agonist treatment, whereas this slower component was not apparent for the M2 and M4 receptors [105]. 
However, these results are not completely consistent with earlier studies. Roseberry and Hosey showed 
in HEK-293 cells that the ectopically expressed M2 receptor was rapidly and to a great extent 
internalized but only minimally degraded after 24 h of carbachol treatment. They even observed some 
degree of recycling of the receptor, albeit very slow, back to the plasma membrane [106]. 
Nevertheless, it is evident that there are differences in the mechanisms involved in receptor 
internalization and downregulation of the M2 receptor as compared to those of the other muscarinic 
receptors. However, special care needs to be taken when comparing studies addressing the trafficking 
and signaling of the receptors as these may be very much dependent on the cell type used.  
M1, M3 and M4 all undergo endocytosis in a clathrin and dynamin dependent manner. Even though it 
is evident that clathrin is not involved in M2 receptor endocytosis, the involvement of caveolin,  
ȕ-arrestins and the GTPase dynamin in this process has remained less conclusive. Although an 
interaction between the M2 receptor and caveolin has been shown in cardiac myocytes [107], M2 receptor 
endocytosis takes place independently of caveolin in HEK-293 cells [108]. Endocytosis of many other 
GPCRs can be inhibited by means of expression of a dominant negative K44A mutant of dynamin2. 
Earlier studies concluded that dynamin would not be required for M2 receptor endocytosis [73], since the 
K44A dynamin2 mutant did not show any effect on M2 receptor endocytosis. More recent studies have 
used other mutants of dynamin2, such as the PIP2 independent K535M and a deletion mutant lacking the 
GTP binding domain. These studies could indeed show that dynamin is involved in M2 receptor 
endocytosis [109,110]. These discrepancies may be explained by unspecific effects of overexpression of 
the K44A and other dynamin mutants on cellular trafficking (Reviewed in [111]). Furthermore, it has 
recently been suggested that some dynamin functions may be independent of its GTPase activity, and 
thus different dynamin2 mutants may impair different steps during trafficking. Unfortunately, the 
dynamin dependency of M2 receptor trafficking has not yet been addressed using the specific chemical 
inhibitors of dynamin, such as Dynasore [112] that have recently become available. 
The stimulation of M1 or M2 receptors OHDGV WR D VWDEOH XELTXLWLQDWLRQ RI ȕ-arrestin in mouse 
embryonic fibroblasts [113]. The internalization of the receptors is not affected by proteasome 
inhibitors but they completely block receptor downregulation which is increased upon expression of a 
FRQVWLWXWLYHO\ XELTXLWLQDWHG ȕ-arrestin. However, the M2 receptor does not seem to undergo 
proteasomal degradation but is rather directed to lysosomes, indicating a role for ȕ-arrestin 
ubiquitination in the correct O\VRVRPDOWDUJHWLQJRIWKHUHFHSWRU8SRQȕ-arrestin ubiquitination, the M2 
receptor DQGȕ-arrestin stably colocalize in intracellular compartments, which was not observed for the 
M1 receptor  [113]. It can be suggested that the pattern of ubiquitLQDWLRQRQȕ-arrestin is important for 
WKHUHFHSWRUWDUJHWLQJDQGWKHVWDEOHDVVRFLDWLRQRIȕ-arrestin and the receptor.  
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Figure 3. Agonist stimulated internalization of the M2 receptor. The M2 receptor is 
internalized by a clathrin-independent, ARF6-dependent pathway. Upon agonist 
stimulation, the M2 receptor is phosphorylated on serine/threonine residues by GRK, which 
IDFLOLWDWHVWKHELQGLQJRIȕ-DUUHVWLQVDQGUHFHSWRUGHVHQVLWL]DWLRQ,QDGGLWLRQWKHȕ-arrestin 
activates ARF6, resulting in M2 receptor internalization in the early endosome. A 
phosphatase dephosphorylates the M2 receptor FDXVLQJ ȕ-arrestin dissociation from the 
receptor. The small G protein Rab22 has been implicated in the recycling of the M2 
receptor. However, recycling appears to be a minor route for the M2 receptor which is 
mainly targeted to lysosomes and degraded. 
 
A protein connected to the M2 receptor whose role is not completely understood so far is the 
Receptor for Activated C Kinase 1 (RACK1), a protein enriched in M2 receptor immunoprecipitates, 
whose interaction with the receptor is disrupted upon treatment with the muscarinic agonist carbachol. 
RACK1 seems to prevent endocytosis, as a decreased expression of RACK1 increases the agonist 
mediated internalization of the receptor. However, at the same time, both overexpression and a 
decrease in RACK1 expression level inhibit receptor downregulation [114]. As RACK1 and  
ȕ-arrestins have overlapping binding sites in the receptors [115], RACK1 might preveQW ȕ-arrestin 
binding to unstimulated receptors. 
4.4. Role of ADP-Ribosylation Factor 6 in the Endocytosis of the M2 Receptor 
The ADP ribosylation factor (ARF) family belongs to the Ras superfamily of GTP binding proteins 
which contains five major subclasses, namely Rab, Rho, Ras, Ran and ARF GTPases [116]. The six 
closely related mammalian ARF proteins are divided in three classes based on their sequence 
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homologies. Accordingly, ARF1, ARF2 and ARF3 belong to class I and ARF4 and ARF5 to class II, 
whereas the sole member of class III is ARF6 [117,118]. As with other GTPases, ARF proteins switch 
between a GTP bound active and a GDP bound inactive form. The cycle of binding and hydrolysis of 
GTP is important for the localization of ARF proteins, and their activation is also connected with the 
membrane localization [118,119]. ARFs are able to interact with a plethora of regulatory proteins such 
as guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Each ARF 
protein exhibits a preference for specialized GAPs and GEFs, and ARFs are specifically recruited to 
cellular compartments in which these regulatory proteins reside [119].  
ARF6, together with ARF1, is the best studied family member of the ARF proteins, and its 
homologues have been found in many eukaryotes, including Xenopus laevis and Drosophila 
melanogaster, as well as in metazoans and fungi, whereas none appear to exist in plants. Similar to all 
members of the ARF family, ARF6 is myristoylated on the N-terminal glycine residue, which is 
important for the membrane association and thus influences the subcellular distribution of ARF6. This 
lipid modification is also essential for the activity of ARF6 in membrane trafficking [120±123] and for 
its membrane localization, as a non-myristoylated ARF6 (Gly2Ala mutation) was not able to bind to 
membranes and remained cytosolic [124].  
ARF6 has been shown to be localized both at the plasma membrane and in endosomal compartments, 
and it evidently plays an important role in the regulation of peripheral membrane dynamics and the 
cortical actin cytoskeleton at the plasma membrane [117,125]. In line with this, ARF6 is a mediator of 
cytoskeletal rearrangements such as the formation of actin-rich plasma membrane protrusions [126,127]. 
ARF6 is also involved in Rac mediated membrane ruffling [126±130], phagocytosis [130] and regulation 
of secretion [131]. Furthermore, activated ARF6 has been indicated to promote the internalization of  
E-cadherin to early endosomes, inducing a disassembly of adherens junctions [132±134]. ARF6 
mediated activation of PLD leads to the activation of phosphatidylinositol 4-phosphate 5-kinase (PIP5K), 
resulting in an increase of PIP2 at the cell periphery [135] where it is involved in clathrin dependent 
endocytic processes [136].  
The requirement of ARF6 in membrane trafficking processes such as endosomal recycling is 
evidenced by the fact that the expression of a dominant negative ARF6 blocks recycling from 
endosomes. Thereafter, several studies have demonstrated the vital role of ARF6 in endosomal 
membrane trafficking [117,124,131,137,138]. Furthermore, ARF6 can regulate both the clathrin 
dependent as well as the clathrin independent endocytosis, but the ARF6 dependent endocytic pathway 
appears to be dynamin independent [133,139]. This is also suggested by the fact that depletion of 
ARF6 affects the endocytosis of several GPCRs, irrespective of their dependency on clathrin [140]. 
During clathrin independent endocytosis, activated ARF6 associates with the adaptor protein complex 
AP2 which mediates the post-endocytic sorting of ARF6 cargos, such as the major histocompatibility 
FRPSOH[,0+&ȕ1-Integrin and the M2 receptor [141]. 
Stimulation of GPCRs not only activates downstream signaling cascades but also leads to 
internalization and desensitization of the respective receptor. In this process, the internalization is 
important for both the resensitization and degradation pathway [142±144]. It has been shown that 
ARF6 is important for the endocytosis of e.g., endothelin type B receptor, vasopressin type 2 receptor 
and the angiotensin type 1 receptor [140]. Stimulation of some GPCRs, VXFK DV ȕ2-adrenergic and 
luteinizing receptors, results in the activation of ARF6, and overexpression of an ARF6 GAP reduces 
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ȕ2-adrenergic receptor internalization [145]. Furthermore, Claing et al. could VKRZ WKDW ȕ-arrestin 
regulates receptor endocytosis through the activation of and interaction with ARF6, thereby providing 
a link between the GPCR and endocytic proteins, such as clathrin and AP2 [146,147].  
The M2 receptor has been demonstrated to be a cargo protein of ARF6 dependent endocytosis. 
Constitutively active ARF6 expression diminished the endocytosis but enhanced the rate and extent of 
recycling of the M2 receptor, implicating that the agonist stimulated internalization and perhaps also 
recycling of the M2 receptor is regulated by ARF6 [109,110,140]. However, a role for ARF6 in the 
ER-Golgi trafficking of GPCRs has also been suggested [148]. Reiner and Nathanson studied the 
involvement of several small G proteins in the regulation of the agonist induced endocytosis of the M2 
receptor [109,110]. The dominant negative T22N mutant ARF6 and Rab22, a GTPase implicated in 
ARF dependent recycling [149], were able to substantially increase the M2 receptor endocytosis. M2 
and M4 receptors initially utilize different endocytic pathways. Only later, they appear to end up in the 
same compartment which is positive for markers of clathrin dependent endocytosis [110]. Thus, the M2 
receptor is initially internalized via a clathrin independent and ARF6 associated pathway, during which 
the M2 receptor is first observed in structures that lack the markers for clathrin dependent endocytosis. 
Thereafter, the M2 receptor internalization pathway quickly merges with the clathrin dependent 
pathway at the level of early endosomes, which contain the early endosome autoantigen 1 (EEA-1) [109].  
5. Muscarinic Acetylcholine Receptors in Human Diseases 
As with most GPCRs, muscarinic receptors are involved in human diseases by distinct mechanisms. 
In various autoimmune diseases, mAChRs frequently are targets of autoantibodies, which bind to the 
receptors and lead either to their activation or inactivation. Initially caused by the parasite Trypanosoma 
cruzi, the Chagas disease may lead to a heart failure and a sudden death upon disease progression. The 
involvement of the heart is possibly connected to the existence of autoantibodies in patients with Chagas 
disease against the M2 receptor, as these receptors display a negative chronotropic effect in cultured 
cardiomyocytes [150,151]. These autoantibodies against M2 receptor have been shown to induce receptor 
crosslinking and internalization due to activation of the receptor [152,153]. 7KH6M|JUHQ¶VV\QGURPHLVD
highly common autoimmune rheumatic disease, which is also connected to autoantibodies directed 
against the muscarinic receptors, among other antigens. Upon progression of the disease, lymphocytes 
infiltrate and attack the lacrimal and salivary glands, leading to dryness of the mouth and the eyes [154]. 
Autoantibodies recognizing the M3 receptor have been shown to be involved, leading to its inhibition and 
internalization. Due to the reduced signaling and impairment of secretion, the salivary flow rate is 
reduced [155,156]. In line with this, knockout mouse studies have shown that M3 receptor, together with 
M1 and M4 receptors, plays a major role in regulating salivary excretion [19].  
Not only autoimmune diseases are related to the muscarinic receptors. In the Achilles tendon from 
patients with tendinosis exhibiting hypercellularity and hypervascularity, a higher level of M2 receptor 
can be observed in the endothelial cells of the vessels as compared to the tendons of healthy patients, 
suggesting the occurrence of acetylcholine and M2 receptor mediated vasodilatory mechanisms in the 
Achilles tendon [157]. Both M2 and M3 receptors affect the bronchial and tracheal smooth muscle 
contraction and are therefore likely to play a role in asthma and chronic obstructive pulmonary disease 
that are accompanied by an increased smooth muscle tone [158]. 
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The expression of muscarinic receptors is described for a variety of cancer cells in which they 
appear to be highly involved in proliferation and migration. In the breast cancer cell line MCF-7, 
stimulation of muscarinic receptors leads to an activation of the ERK pathway in a manner dependent 
on PKC-ȗSKRVSKRLQRVLWLGH-kinase and a kinase of the Src family, increasing protein biosynthesis 
and cell proliferation [159]. A stimulatory effect on cell migration was shown for HeLa cells in an 
ERK1/2 dependent mechanism [160]. In addition, muscarinic receptors are thought to play a role in 
angiogenesis in breast cancer [161]. A cancer type that overexpresses muscarinic receptors is colon 
cancer, in which high levels of M3 receptors have been found to mediate cancer cell 
proliferation [162], and the M3 receptor is involved in cell migration of these cells via the release of 
MMPs and transactivation of EGF receptors [163,164]. This is clearly different from the influence of 
muscarinic receptors on the migration of keratinocytes, where the M3 receptor is rather inhibiting cell 
migration than promoting it [27].  
Whereas M3 receptors stimulate cell proliferation of tumor cells, M2 receptors seem to have a 
contrary effect. A specific cancer type that is influenced by this muscarinic receptor is glioblastoma, a 
common brain tumor. In glioblastoma cell lines, addition of the M2 receptor agonist arecaidine 
decreased cell growth in a time and dose dependent manner and was counteracted by the M2 receptor 
antagonist gallamine. In contrast, muscarine had no significant influence on proliferation [165]. The 
effect of cholinergic ligands on small cell lung carcinoma cells is more controversial. On the one hand, 
cholinergic stimulation of the small cell lung cancer cells H69 enhances cell proliferation [166], but on 
the other hand, the SCC-9 cell line is inhibited in cell cycle progression upon cholinergic stimulation 
and shows a diminished DNA synthesis [167]. Another cell type that uses acetylcholine as a growth 
factor is hepatocellular carcinoma. In cancer tissues, the acetylcholinesterase is often downregulated 
and its decrease correlates with tumor aggressiveness [168]. Due to the diminished expression of 
acetylcholinesterase, acetylcholine cannot be hydrolyzed. It is likely that the elevated level of 
acetylcholine acts on muscarinic receptors of the tumor cells and therefore increases their proliferation. 
The above observations reveal how different the influence of muscarinic receptors on specific cells is, 
depending on the cellular environment and the cellular proteome. However, although muscarinic 
receptors sometimes exhibit unpredictable or unexpected effects on cancer progression, they still might 
be an interesting target for therapeutic drugs in the future. 
6. Conclusions and Future Challenges  
In tissues, the effects of acetylcholine are mediated by the repertoire of the receptor subtypes 
expressed, and both nicotinic and muscarinic receptors contribute to the cellular response observed. 
Since a certain cell type normally expresses more than one type of acetylcholine receptor, the cellular 
response is often a compiled one, with a contribution of several subtypes. Furthermore, the observed 
effects on the cell physiology are also dependent on the class of the G protein subunits and their 
modulators expressed by the specific cell type. Thus, the interpretation of the data resulting from 
studies in various cell types may be a complicated task. Some specific physiological functions of 
muscarinic receptor subtypes have been revealed by the studies on knockout mouse models (Reviewed 
in [169]). However, even in this system, one needs to be cautious since loss of one subtype may result 
in aberrant desensitization of another one due to a hypercholinergic status produced by the lack of the 
major receptor subtype in a certain tissue [170]. 
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Pharmacological substances that result in the activation of only either of the receptor groups are 
available. However, the activation or even inhibition of a specific receptor subtype is notoriously 
difficult, as the substances used are rarely fully specific for a single receptor subtype. With increasing 
knowledge about the structural differences of the receptors, it may become possible to develop novel 
compounds that specifically affect the functions of a single subtype. Thereby, special interest has been 
paid on ligands that bind to allosteric regulatory sites. Intriguingly, the structure of the M2 receptor was 
recently solved [74] and revealed some important structural features specific for this subtype that may 
facilitate the generation of more selective drugs in the future.  
Older studies have frequently been performed using overexpression of a specific receptor subtype. 
However, if the receptor expression level is too high, this may even result in saturation of signaling or 
WUDIILFNLQJSDUWQHUV³GRPLQDQWQHJDWLYHHIIHFW´DQGWKXVPLVLQWHUSUHWDWLRQRIWKHUHVXOWV Furthermore, 
other receptors expressed in the cell type still contribute to the signaling response although the 
overexpressed one may be predominant. The discovery of specific gene knockdown strategies in cell 
culture, e.g., RNA interference, has provided better options to modulate the signaling in the target cells 
by depleting a specific receptor subtype. However, even this is not completely secure, as the other 
receptor subtypes expressed may compensate for the loss of another one. Interestingly, mouse 
embryonic fibroblast have been described not to contain mRNA or protein for any of the muscarinic 
receptors [97]. Thus, this cell type may be especially suitable for studies addressing the subtype 
specific signaling, provided that the required partners are also expressed. 
Future challenges in the studies of non-neuronal functions of muscarinic receptors will certainly 
include revisiting the data obtained in various cell systems and by means of receptor overexpression. It 
will be of special importance to compile these data in a model that needs to be tested in a single system 
that allows definite conclusions on the function of a single receptor type. Special effort should also be 
dedicated to novel pharmaceutical compounds, both inhibitors and activators, which affect the function 
of only a specific muscarinic receptor. With these tools at hand, it will be possible to obtain a more 
conclusive picture about the non-neuronal functions of this receptor class.  
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